The Federal Trade Commission (FTC) recently sued the three largest pharmacy benefit managers (PBMs ... engage in treatment involving expensive drug products. The complaint argues that the ...

largest pharmacy benefit managers for their alleged role ... fact-based assessment of PBMs or the prescription drug market,” contending that the FTC “completely overlooks the volumes of ...

Elizabeth Warren seeks scrutiny of deals that would allow drug middlemen McKesson, Cardinal Health, and Cencora to also ...

The owner of one of the three largest pharmacy middlemen in the United States last month filed suit to quash an attempt by the Federal Trade Commission to investigate industry ...

FTC accuses CVS, Cigna, and UnitedHealth of driving up insulin prices through rebates. PBMs administer 80% of U.S. prescriptions and allegedly inflate life-saving insulin costs. The complaint ...

The Federal Trade Commission’s study of pharmacy benefit managers’ effect on the prescription-drug market is one of ... who is often critical of the FTC. On this point, however, we are ...

CVS Health, Cigna and UnitedHealth Group are demanding that FTC Chairwoman Lina Khan and two other commissioners recuse themselves from a lawsuit accusing the company and other drug middlemen of ...

CVS Health Corp. and UnitedHealth Group Inc. said members of the US Federal Trade Commission who voted to sue prescription ... by the FTC commissioners criticizing pharmacy benefit managers ...

The FTC declined to comment ... that deploy deceptive subscription models to trap customers are trying to sue their way out of this regulation to lower costs for millions of consumers,” Liz ...

Three groups that represent businesses are suing the FTC to block the Biden administration's new 'Click to Cancel' rule.

The rules are a game-changer that supporters say will require companies to be more transparent and take the burden off regulators in trying to prevent illegal mergers and acquisitions. Opponents argue ...

A pharmacy benefit manager ... Trade Commission (FTC), taking issue with the agency's recent report accusing PBMs of using anti-competitive practices to drive up prescription drug prices.